Donna Grogan - Hudson MA, US Larry Bush - Worcester MA, US
International Classification:
A61K031/455 A61K031/4184 A61K031/41
US Classification:
514355000, 514381000
Abstract:
A pharmaceutical composition comprising enantiomerically pure (S)-amlodipine malate, an ARB and optional other active agents, and methods of treating, preventing and managing cardiovascular diseases and disorders, and symptoms thereof, using the composition, are disclosed.
Compositions Comprising (S)-Amlodipine And An Angiotensin Receptor Blocker And Methods Of Their Use
Donna Grogan - Hudson MA, US Larry Bush - Worcester MA, US
International Classification:
A61K031/455 A61K031/4184
US Classification:
514355000, 514381000
Abstract:
A pharmaceutical composition comprising enantiomerically pure (S)-amlodipine, an ARB and optional other active agents, and methods of treating, preventing and managing cardiovascular diseases and disorders, and symptoms thereof, using the composition, are disclosed.
The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
- Montreal, CA Michael HARVEY - Kirkland, CA Donna Roy GROGAN - Boston MA, US Clarissa DESJARDINS - Westmount, CA
International Classification:
A61K 31/415 A61P 19/00 A61K 9/00
Abstract:
The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.
- Montreal, CA Donna Roy GROGAN - Boston MA, US Jeffrey Neal PACKMAN - Weston MA, US Mark HARNETT - Stow MA, US
International Classification:
A61K 31/415 A61P 19/08 A61P 19/04 A61K 9/00
Abstract:
The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
Antisense Oligonucleotides And Methods Of Use Thereof
The invention is directed to antisense oligonucleotides that hybridize to the mRNA from a mutant activin A receptor type-1 (ACVR1) gene and inhibit or reduce the expression of the mutant ACVR1 gene. The mutant ACVR1 gene has the mutation c.617G>A. The invention also features pharmaceutical compositions including the antisense oligonucleotides and methods of using the antisense oligonucleotides to treat diseases or conditions (e.g., FOP and DIPG) associated with the expression of the mutant ACVR1 gene.
Name / Title
Company / Classification
Phones & Addresses
Donna Roy Grogan
Donna Grogan MD Internist
55 Lk Ave N, Worcester, MA 01655 508 357-7608
Donna Grogan Chief Medical Officer
FOLDRX PHARMACEUTICALS, INC Noncommercial Medical Research Organization
100 Acorn Park Dr, Cambridge, MA 02140 100 Acorn Park, Cambridge, MA 02140 500 Arcola Rd, Collegeville, PA 19426 617 252-5500
Grogan Consulting
Principal
Clementia Pharmaceuticals Inc. Sep 2013 - Jul 2019
Director, Chief Medical Officer
Health Care Venture Focused Companies Mar 2012 - Aug 2013
Medical Officer
Foldrx Pharmaceuticals 2007 - Aug 2011
Chief Medical Officer
Sunovion Pharmaceuticals Inc. 2005 - 2007
Senior Vice President Clinical Research
Education:
University of Illinois College of Medicine 1979 - 1983
Doctor of Medicine, Doctorates
College of the Holy Cross 1974 - 1978
Bachelors, Bachelor of Arts, Psychology
Robin Harrelson, Larry Clark, Michael Kittrell, Linda Phillips, Bobby Atkins, Sherri Moorefield, Judi Putnam, Misty May, Debbie Herndon, James Parker, Diane Notsure